Sklamberg Quoted in The Pink Sheet on FDA Inspections During Pandemic

Life Sciences and Healthcare Regulatory partner Howard Sklamberg was quoted in a recent article from The Pink Sheet, "US FDA Invites Warning Letter Follow-Up Inspection Alternative Proposals As Pandemic Persists." The article discusses the issues caused by the forced grounding of FDA inspections and follow-up site visits during the coronavirus pandemic.

» Read the full article (subscription required).